Abstract Library

#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)

Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C,

Keywords: alkylating agents, pancreatic NET, re-challenge, chemotherapy,

#1769 Minimal Risk of Persistent or Recurrent Hypoglycemia after MEN1-Related Insulinoma Surgery. A Large International Cohort Study

Introduction: Current literature states that 15-30% of the MEN1 patients suffer from hypoglycemia after insulinoma surgery.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Nell S

Authors: Nell S, Goudet P on behalf of the French Endocrine Tumor Study Group (GT -, Vella A, Bartsch D, Perrier N,

Keywords: MEN1,